CINECA IRIS Institutional Research Information System

LEONE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.357
AS - Asia 5.961
EU - Europa 4.473
SA - Sud America 603
AF - Africa 114
OC - Oceania 103
Continente sconosciuto - Info sul continente non disponibili 12
Totale 19.623
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.073
CN - Cina 2.528
SG - Singapore 1.386
IT - Italia 1.107
DE - Germania 600
FR - Francia 461
BR - Brasile 457
JP - Giappone 450
GB - Regno Unito 419
VN - Vietnam 382
IE - Irlanda 292
ES - Italia 279
IN - India 245
FI - Finlandia 233
SE - Svezia 221
KR - Corea 191
CA - Canada 182
HK - Hong Kong 177
UA - Ucraina 126
TR - Turchia 120
PL - Polonia 97
NL - Olanda 94
TW - Taiwan 92
AU - Australia 86
BE - Belgio 75
CH - Svizzera 74
RU - Federazione Russa 66
MX - Messico 65
ID - Indonesia 62
AR - Argentina 59
TH - Thailandia 58
AT - Austria 56
GR - Grecia 54
BD - Bangladesh 38
SA - Arabia Saudita 36
PT - Portogallo 35
RO - Romania 33
CZ - Repubblica Ceca 30
IQ - Iraq 27
DK - Danimarca 26
IR - Iran 25
EG - Egitto 23
PK - Pakistan 22
MY - Malesia 21
ZA - Sudafrica 21
CL - Cile 18
IL - Israele 17
NZ - Nuova Zelanda 17
CO - Colombia 16
HU - Ungheria 15
PE - Perù 15
EC - Ecuador 14
KE - Kenya 12
MA - Marocco 11
JO - Giordania 10
LB - Libano 10
PH - Filippine 10
EU - Europa 9
HR - Croazia 9
JM - Giamaica 9
NO - Norvegia 8
SI - Slovenia 8
TN - Tunisia 8
BG - Bulgaria 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
UY - Uruguay 7
VE - Venezuela 7
LV - Lettonia 6
NP - Nepal 6
SK - Slovacchia (Repubblica Slovacca) 6
AE - Emirati Arabi Uniti 5
AM - Armenia 5
ET - Etiopia 5
KZ - Kazakistan 5
OM - Oman 5
QA - Qatar 5
SN - Senegal 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
BO - Bolivia 4
CR - Costa Rica 4
EE - Estonia 4
GE - Georgia 4
LT - Lituania 4
LU - Lussemburgo 4
MK - Macedonia 4
NG - Nigeria 4
PY - Paraguay 4
UZ - Uzbekistan 4
AP - ???statistics.table.value.countryCode.AP??? 3
BN - Brunei Darussalam 3
BY - Bielorussia 3
GA - Gabon 3
HN - Honduras 3
IS - Islanda 3
MT - Malta 3
PA - Panama 3
PR - Porto Rico 3
TT - Trinidad e Tobago 3
Totale 19.586
Salva come PNG Salva come JPEG
Città #
Singapore 751
Beijing 676
San Jose 587
Ashburn 532
Chandler 485
Fairfield 386
Santa Clara 356
Houston 347
Shanghai 327
Dublin 289
Woodbridge 210
Seattle 208
Wilmington 203
Ann Arbor 195
Redwood City 164
Torino 152
Cambridge 149
Tokyo 145
Los Angeles 138
Guangzhou 137
New York 129
Dearborn 122
Villeurbanne 122
Nyköping 116
Jacksonville 109
Milan 108
Ho Chi Minh City 107
Columbus 103
Pisa 102
Helsinki 97
Princeton 97
Nanjing 91
The Dalles 90
Hong Kong 88
Medford 88
Munich 87
Lauterbourg 83
Dallas 82
Warsaw 78
Seoul 68
Hefei 64
Hangzhou 63
Boston 61
Hanoi 60
Wuhan 60
Zhengzhou 59
Dong Ket 57
Istanbul 55
Turin 55
São Paulo 54
Chengdu 53
London 53
Taipei 53
Paris 50
Rome 50
Buffalo 49
San Diego 48
Chicago 46
Madrid 46
Jakarta 45
Barcelona 44
Toronto 44
Duncan 41
Boardman 39
Jinan 38
Council Bluffs 35
Brussels 33
Amsterdam 32
Atlanta 32
Phoenix 29
Silver Spring 29
Tianjin 29
Montreal 28
Mumbai 28
Norwalk 26
Ottawa 26
Shenyang 26
Bengaluru 25
Redondo Beach 25
Philadelphia 24
San Francisco 24
Nuremberg 23
Sydney 23
Salt Lake City 22
Bangkok 21
Shenzhen 21
Turku 21
Berlin 20
Frankfurt am Main 20
Fremont 20
Manchester 20
Washington 20
Aioicho 19
Chongqing 19
Denver 19
Melbourne 19
Riyadh 18
Verona 18
Changsha 17
Da Nang 16
Totale 10.518
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 6.205
Emerging molecular target antagonists for the treatment of biliary tract cancer 748
A phase I dose-escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. 536
Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy. 340
Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18 F-FDG PET and MRI radiomics features 334
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) 320
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy 290
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 273
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma 217
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 216
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 209
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 208
Fluoropyrimidine-induced cardiotoxicity 199
The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results from a Large Retrospective Study. 199
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine 197
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: A case report 196
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR 191
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 190
Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients 190
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 182
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. 180
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: A multicenter survey and pooled analysis with published data 171
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 170
Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? 168
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives 166
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas 164
Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line 163
PHASE II TRIAL OF PANITUMUMAB IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE CHEMOTHERAPY AS 1ST LINE THERAPY IN PATIENTS WITH COLORECTAL CANCER AND ADVANCED LIVER METASTASES: THE METAPAN STUDY 159
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient 155
Antitumor activity of Src inhibitor Saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. 150
Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives 149
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 148
Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab 142
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases: The MetaPan study. 141
Bone metastases in biliary cancers: A multicenter retrospective survey 141
A novel multidrug‐resistant cell line from an italian intrahepatic cholangiocarcinoma patient 139
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer 138
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 137
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 133
Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy 131
High prevalence of hepatitis C virus (HCV) genotype 2 in Italian patients with chronic liver disease. 131
Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. 128
[Diagnosis of neoplastic ascites: combined use of albumin gradient between serum and ascites and cholesterol in ascitic fluid] 127
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 123
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial 123
LONG-TERM SURVIVAL OF PATIENTS WITH RESECTION OF PULMONARY METASTASES FROM COLORECTAL NEOPLASMS AS COMPARED TO NOT RESECTED ONES. A RETROSPECTIVE STUDY ON PATIENTS FOLLOWED FROM THE TIME OF FIRST RECURRENCE 122
Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma 122
Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study 121
Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. 120
Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT) 119
GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. 114
Biliary tract carcinomas: From chemotherapy to targeted therapy. 113
Diagnostic paracentesis. A two-step approach. 111
Epidemiological and virological analysis of couples infected with hepatitis C virus. 111
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study 111
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 111
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 110
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy 108
Adjuvant chemotherapy and follow-up 107
Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles 106
Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors 106
Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience 105
“Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer 105
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 104
Linifanib: Current status and future potential in cancer therapy 103
Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients 103
Evaluation of iron status in patients with chronic hepatitis C. 102
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 101
Targeted agents: how can we improve the outcome in biliary tract cancer? 97
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 97
Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach 96
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 95
Phlebotomy reduces serum procollagen III peptide levels in patients with chronic hepatitis C. 94
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 92
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 89
Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer 89
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 88
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 87
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer 87
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 86
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. 84
Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: A single institutional experience. 81
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 80
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma 79
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 78
Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma 77
Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. 76
Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. 76
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 70
Cartoon: Multicenter prospective observational study of Cardiovascular Toxicity of Trifluridine/Tipiracil in metastatic colorectal cancer 68
Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma 68
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 68
Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer 66
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 64
Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. 63
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 58
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 56
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 53
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database 33
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry 4
Totale 20.051
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.867
article - articoli 0
book - libri 0
conference - conferenze 1.261
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.128
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021194 0 0 0 0 0 0 0 0 0 0 0 194
2021/20221.678 132 139 97 109 134 98 135 145 92 93 288 216
2022/20231.924 193 178 73 172 161 350 152 126 200 92 140 87
2023/20241.436 145 179 112 116 115 146 101 118 28 93 138 145
2024/20252.714 73 187 167 235 500 220 112 159 324 191 230 316
2025/20264.722 489 260 316 471 478 261 631 214 418 668 253 263
Totale 20.051